SCHEMBL5038641

SCHEMBL5038641

COC(C(=O)O)c1ccc(C(F)(F)F)cc1C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.46
POLQ O75417 3/20 0.42
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 2/20 0.41
ABCB11 O95342 1/20 0.40
PPARG P37231 4/20 0.40
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
CFTR P13569 1/20 0.40
PDE2A O00408 3/20 0.40
CYP2C19 P33261 2/20 0.39
USP2 O75604 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
AKR1C3 P42330 1/20 0.39
AKR1C2 P52895 1/20 0.39
PPARA Q07869 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5042110 0.85 PDE2A (0.54) KDM4EALDH1A1HPGDHSD17B10PPARG
SCHEMBL5041168 0.82 IDO1 (0.46) KDM4EALDH1A1HPGDHSD17B10PPARG
SCHEMBL30428378 0.80 CES2 (0.50) CES2POLQKDM4EALDH1A1PDE2A
SCHEMBL2703078 0.80 ACP3 (0.46) POLQHPGDPPARGAKR1C3AKR1C2
SCHEMBL2346776 0.80 ACP3 (0.46) POLQHPGDPPARGAKR1C3AKR1C2
SCHEMBL2351342 0.80 ACP3 (0.46) POLQHPGDPPARGAKR1C3AKR1C2
Hydrochloric Acid SCHEMBL5595953 0.78 ACP3 (0.45) POLQHPGDPPARGAKR1C3AKR1C2
SCHEMBL10334614 0.78 RXRA (0.46) CES2POLQPPARGRXRARXRB
SCHEMBL6681459 0.78 CES2 (0.51) CES2POLQKDM4EALDH1A1HPGD
SCHEMBL6681467 0.78 CES2 (0.51) CES2POLQKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567498-B1 MANDELIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-23 EP disclosed
US-7129238-B2 Mandelic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2006-10-31 US disclosed
EP-1567498-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-08-31 EP disclosed
US-20040122057-A1 Novel mandelic acid derivatives HOFFMANN-LA ROCHE INC. 2004-06-24 US disclosed
WO-2004048335-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122057-A1 Novel mandelic acid derivatives F7, F11, F9 CES2 3770/4885POLQ 4449/4885KDM4E 2563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.